NorthWest Biotherapeutics Inc (NWBO)

[beachhyena]

Another point to remember based on the following.

Quote:

….the Company is required to pay certain fees for dedicated production capacity reserved exclusively for DCVax production, and pay for manufacturing of DCVax-L products for a certain minimum number of patients, whether or not the Company fully utilizes the dedicated capacity and number of patients. Either party may terminate the MSA on twelve months’ notice, to allow for transition arrangements by both parties.

If the company has been sitting on a failed trial how is it legal for them to continue paying Advent fees for a failed product utilizing Shareholder money to do so.

My thinking is that the above statement should be seen as a positive if NWBO has continued to pay these fees up to the present day.